Omicron: what makes the latest SARS-CoV-2 variant of concern so concerning?
Emerging strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
causative agent of the coronavirus disease 2019 (COVID-19) pandemic, that show …
causative agent of the coronavirus disease 2019 (COVID-19) pandemic, that show …
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
YW Zhou, Y Xie, LS Tang, D Pu, YJ Zhu… - Signal transduction and …, 2021 - nature.com
Owing to the limitations of the present efforts on drug discovery against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lack of the understanding of the …
respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lack of the understanding of the …
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
J Ai, H Zhang, Y Zhang, K Lin, Y Zhang… - Emerging microbes & …, 2022 - Taylor & Francis
The emerging new VOC B. 1.1. 529 (Omicron) variant has raised serious concerns due to
multiple mutations, reported significant immune escape, and unprecedented rapid …
multiple mutations, reported significant immune escape, and unprecedented rapid …
[HTML][HTML] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone
progressive change, with variants conferring advantage rapidly becoming dominant …
progressive change, with variants conferring advantage rapidly becoming dominant …
Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant
We report that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta spike
mutation P681R plays a key role in the Alpha-to-Delta variant replacement during the …
mutation P681R plays a key role in the Alpha-to-Delta variant replacement during the …
Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera
The race to produce vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) began when the first sequence was published, and this forms the basis for …
(SARS-CoV-2) began when the first sequence was published, and this forms the basis for …
[HTML][HTML] Antibody evasion by the P. 1 strain of SARS-CoV-2
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
We engineered three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
viruses containing key spike mutations from the newly emerged United Kingdom (UK) and …
viruses containing key spike mutations from the newly emerged United Kingdom (UK) and …
BNT162b2-elicited neutralization of B. 1.617 and other SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve
around the world, generating new variants that are of concern on the basis of their potential …
around the world, generating new variants that are of concern on the basis of their potential …
The N501Y spike substitution enhances SARS-CoV-2 infection and transmission
Abstract The B. 1.1. 7 variant (also known as Alpha) of SARS-CoV-2, the cause of the COVID-
19 pandemic, emerged in the UK in the summer of 2020. The prevalence of this variant …
19 pandemic, emerged in the UK in the summer of 2020. The prevalence of this variant …